Gabapentin NDC 31722-091

NDC codes

FDA NDC Directory

Product NDC (as listed)31722-091Labeler and product segments. Claims need a package NDC.

Product NDC at billing width31722-0091Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
31722-091-90	31722009190	90 TABLET, FILM COATED in 1 BOTTLE (31722-091-90)Marketed from Feb 26, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Gabapentin
Generic name (nonproprietary): gabapentin
Active ingredients: Gabapentin — 300 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Camber Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 218075
Marketing start: Feb 26, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 31722-091_360950f4-eef0-54cb-e063-6394a90aa5d6SPL ID 360950f4-eef0-54cb-e063-6394a90aa5d6SPL set ID 0ce53f62-1738-43f4-9a2e-c5dc42a91d09RxCUI 1806380, 1806382UNII 6CW7F3G59XUPC 0331722091909

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N431722009190 followed by a unit qualifier and the quantity

Package 31722-0091-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 26, 2025.

Indications (excerpt from the label)

Gabapentin tablets are indicated for the management of postherpetic neuralgia. Gabapentin tablets are not substitutable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration. Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN). Important Limitation: Gabapentin tablets are not substitutable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration (See Warnings and Precautions )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 218075

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 218075
Product	Strength	Form · route	Labeler	Product NDC
Gabapentin	Gabapentin 600 mg/1	Tablet, Film coatedOral	Camber Pharmaceuticals, Inc.	31722-092